Smith & Nephew hosts thought-leading surgeons, showcases new technology at
American Academy of Orthopaedic Surgeons annual meeting
LONDON, March 18, 2013
LONDON, March 18, 2013 /PRNewswire/ --Smith & Nephew (LSE: SN NYSE: SNN), the
global medical technology business, is set to showcase its advanced portfolio
of medical devices at this year's American Academy of Orthopaedic Surgeons
(AAOS) meeting in Chicago, March 19-23.
New products highlighted at the show include the recently launched REDAPT™ Hip
Revision System, the JOURNEY™ II BCS Knee, which incorporates VERILAST™
Technology in a knee replacement system that restores the anatomical shapes
and more normal motion of the human knee, and a new Modular Rail System for
deformity correction and limb restoration that was designed in collaboration
with Dror Paley, MD.
Further illustrating the company's increased, strategic investment in
fast-growing areas of the orthopaedic market is the ALL28™ foot and ankle
portfolio, and a suite of industry-leading sports medicine technologies,
including the FAST-FIX™ 360 Meniscal Repair System, the DYONICS™ Platinum
Series Blades, and HEALICOIL™ PK, BIORAPTOR™ and OSTEORAPTOR™ Suture Anchors
for joint repair.
Also highlighted will be the company's Advanced Wound Management (AWM)
surgical incision management portfolio, led by the single-use, pocket-sized
PICO™ Negative Pressure Wound Therapy system, one of a number of AWM products
that can help reduce orthopaedic surgical site complications, such as
dehiscence or edema.
Additionally, a group of thought-leading orthopaedic surgeons, including Marc
Philippon, MD, and Dror Paley, MD, will share their latest clinical results
and innovative techniques as part of the Daily Workshop Series in Smith &
Nephew's booth (booth #1218).
For the full schedule of speakers and featured technologies, visit Smith &
Nephew's dedicated AAOS meeting website www.PowerSmithNephew.com. While at the
show, follow the company on Twitter (@smithnephew) and Facebook
(facebook.com/smithandnephew) for regular updates.
About Smith & Nephew
Smith & Nephew is a global medical technology business dedicated to helping
improve people's lives. With leadership positions in Orthopaedic
Reconstruction, Advanced Wound Management, Sports Medicine and Trauma, Smith &
Nephew has almost 10,500 employees and a presence in more than 90 countries.
Annual sales in 2012 were more than $4.1 billion. Smith & Nephew is a member
of the FTSE100 (LSE: SN, NYSE: SNN).
For more information about Smith & Nephew, please visit: www.smith-nephew.com
This document may contain forward-looking statements that may or may not prove
accurate. For example, statements regarding expected revenue growth and
trading margins, market trends and our product pipeline are forward-looking
statements. Phrases such as "aim", "plan", "intend", "anticipate",
"well-placed", "believe", "estimate", "expect", "target", "consider" and
similar expressions are generally intended to identify forward-looking
statements. Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual results to
differ materially from what is expressed or implied by the statements. For
Smith & Nephew, these factors include: economic and financial conditions in
the markets we serve, especially those affecting health care providers, payors
and customers; price levels for established and innovative medical devices;
developments in medical technology; regulatory approvals, reimbursement
decisions or other government actions; product defects or recalls; litigation
relating to patent or other claims; legal compliance risks and related
investigative, remedial or enforcement actions; strategic actions, including
acquisitions and dispositions, our success in integrating acquired businesses,
and disruption that may result from changes we make in our business plans or
organisation to adapt to market developments; and numerous other matters that
affect us or our markets, including those of a political, economic, business
or competitive nature. Please refer to the documents that Smith & Nephew has
filed with the U.S. Securities and Exchange Commission under the U.S.
Securities Exchange Act of 1934, as amended, including Smith & Nephew's most
recent annual report on Form 20-F, for a discussion of certain of these
Any forward-looking statement is based on information available to Smith &
Nephew as of the date of the statement. All written or oral forward-looking
statements attributable to Smith & Nephew are qualified by this caution. Smith
& Nephew does not undertake any obligation to update or revise any
forward-looking statement to reflect any change in circumstances or in Smith &
Trademark of Smith & Nephew. Registered US Patent and Trademark Office.
SOURCE Smith & Nephew
Contact: Andrew Burns, Media Enquires, Smith & Nephew, +1-901-399-5739,
Andrew.Burns@smith-nephew.com, or Phil Cowdy, Investor/Analyst Enquires, Smith
& Nephew, 44 (0)20 7401 7646, Phil.Cowdy@smith-nephew.com
Press spacebar to pause and continue. Press esc to stop.